Clinical trials: Resistant Infection
Tuberculosis, Multidrug-Resistant, Extensively Drug-Resistant Tuberculosis
Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)
TB PRACTECAL is a multi-centre, open label, multi-arm, randomised, controlled, phase II-III trial; evaluating short treatment regimens containing bedaquiline and pretomanid in combination with existing and re-purposed anti-TB…
- Conditions
- Tuberculosis, Multidrug-Resistant, Extensively Drug-Resistant Tuberculosis, Tuberculosis, Pulmonary
- Trial name
- TB-PRACTECAL (NCT02589782)
- Testing
- Bedaquiline, Pretomanid, Moxifloxacin
- Where
- 7 sites in Belarus, South Africa and 1 more
- Volunteers
- 552 people
- Sponsor
- Medecins Sans Frontieres, Netherlands
Multi-Drug Resistant Hiv-1 Infection, HIV-1 Infection
A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection
Background: People with HIV usually take a combination of 2 or more anti-HIV drugs daily to help manage their infection. Sometimes, however, HIV becomes resistant to these drugs, and the infection cannot be treated.
- Trial name
- NCT05582694
- Testing
- UB-421
- Where
- United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza-like Illness
Biobran/MGN-3 Increases Innate Resistance and Reduces the Incidence of Influenza-like Illnesses
Influenza is a seasonally-epidemic viral infection causing 3-5 million severe illnesses and up to approximately 500,000 annual deaths around the world.
- Trial name
- NCT04646980
- Testing
- Biobran/MGN-3
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Zagazig University
Staphylococcus (S.) Aureus Infection
Staphylococcus Aureus Caught in Action at the Site of Infection
This study is to obtain a comprehensive view of S. aureus adaptations in the infected human host and (i) to improve the understanding of the interface between antibiotic therapy, resistance development and virulence factor…
- Trial name
- PROSA (NCT04781569)
- Testing
- data collection, blood draw, nose swabs
- Where
- Switzerland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Covid19
CISCO-21 Prevent and Treat Long COVID-19.
Many people have long-lasting symptoms after COVID-19, such as breathlessness, fatigue and chest pain. So far, research studies of treatments for COVID-19 have focused on the life-threatening acute illness; few studies look at…
- Trial name
- CISCO-21 (NCT04900961)
- Testing
- Resistance Exercise
- Where
- 2 sites in United Kingdom
- Volunteers
- 233 people
- Sponsor
- NHS Greater Glasgow and Clyde
Infection, Human Immunodeficiency Virus
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
Integrase is an enzyme produced by HIV so that the virus can multiply in the human body. GSK1349572 is a new drug in the integrase inhibitor class that prevents the enzyme from working properly and therefore prevents the virus…
- Trial name
- NCT00950859
- Testing
- GSK1349572 (Cohort I), GSK1349572 (Cohort II)
- Where
- 26 sites in United States, Canada and 3 more
- Volunteers
- 51 people
- Sponsor
- ViiV Healthcare
Lung Infection, Microbial Colonization
FMT for Lung and Associated-organ Rescue Efficacy in MDRO-infected Ventilated Patients
Multidrug-resistant organism (MDRO)-infection represents a substantial global health burden. In the intensive care unit (ICU), the concurrent administration of antibiotics, opioids, proton pump inhibitors (PPIs)…
- Conditions
- Lung Infection, Microbial Colonization, Food Intolerance Syndromes
- Trial name
- FLARE-MV (NCT06970262)
- Testing
- Fecal suspension
- Where
- China
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Mediterranean Fever, Colchicine Resistance
Study of Colchicine Resistance in Familial Mediterranean Fever
Five to 10% of familial mediterranean patients are considered colchicine-resistant (i.e. patients with a persistent inflammatory syndrome, despite taking the maximum tolerated dose of colchicine daily).
- Trial name
- COLCHI-RESIST (NCT05418686)
- Testing
- Capillary colchicine dosage in colchicine-resistant Familial Mediterranean Fever patients.
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Bloodstream Infections (BSI) Due to CRE, Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE
A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
This was a Phase 3 study containing a randomized open-label superiority cohort (Cohort 1) comparing the efficacy and safety of plazomicin with colistin when combined with a second antibiotic (either meropenem or tigecycline) in…
- Conditions
- Bloodstream Infections (BSI) Due to CRE, Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE, Ventilator-Associated Bacterial Pneumonia (VABP) Due to CRE, Complicated Urinary Tract Infection (cUTI) Due to CRE
- Trial name
- CARE (NCT01970371)
- Testing
- plazomicin, colistin, meropenem
- Volunteers
- 69 people
- Sponsor
- Achaogen, Inc.
CF - Cystic Fibrosis, Klebsiella Pneumoniae Infection
Safety of Combined Intravenous Antibiotic and Bacteriophage Therapy in Adults With Cystic Fibrosis and Antibiotic-Resistant Lung Infections
This is a Phase 1, open-label, multi-center pilot study evaluating the safety and microbiological activity of intravenous (IV) bacteriophage therapy in combination with standard IV antibiotics in adults with cystic fibrosis (CF)…
- Conditions
- CF - Cystic Fibrosis, Klebsiella Pneumoniae Infection, E Coli Infections, Staphylococcus Aureus Infection
- Trial name
- NCT07280598
- Testing
- Intravenous Bacteriophage Cocktail plus Standard IV Antibiotics
- Volunteers
- 30 people
- Sponsor
- University of California, San Diego
Nosocomial Infections, MRSA Colonization
Comparison of Two Protocols to Prevent the Acquisition of Methicillin-Resistant Staphylococcus Aureus.
Nosocomial infections is a major problem in intensive care units due to both growing incidence and pathogens implicated which become increasingly resistant to antibiotics.
- Trial name
- NCT00151606
- Testing
- Reinforced isolation + Muciprocine
- Where
- 2 sites in France
- Volunteers
- 500 people
- Sponsor
- Rennes University Hospital
Acinetobacter Baumannii Infection
Comparison of the Clinical Efficacy of Ampicillin/Sulbactam and Cefoperazone/Sulbactam Against Multidrug Resistant Acinetobacter Baumannii Infections in Critically Ill Patients
To compare the clinical effectiveness of two different sulbactam-based regimens (ampicillin-sulbactam versus cefoperazone-sulbactam) in the treatment of Acinetobacter baumannii infections in critically ill patients.
- Trial name
- NCT07118384
- Testing
- Cefoperazone-sulbactam injection, Ampicillin - Sulbactam Injection
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Cairo University
Pulmonary Tuberculosis
Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002)
The purpose of this study is to assess the mycobactericidal activity of the moxifloxacin plus PA-824 plus pyrazinamide regimen after 8 weeks of treatment.
- Trial name
- NCT01498419
- Testing
- Moxifloxacin (M), Pretomid (Pa), Pyrazinamide (Z)
- Where
- 8 sites in South Africa, Tanzania
- Volunteers
- 207 people
- Sponsor
- Global Alliance for TB Drug Development
Helicobacter Pylori Infection
Helicobacter Pylori Eradication According to DPO-PCR Methods (K-CREATE) Study)
Clarithromycin-containing triple therapy is still the primary therapy approved by the Korean government. However, studies of antibiotic resistance have shown that regional resistance patterns to antibiotics such as clarithromycin…
- Trial name
- NCT04147065
- Testing
- Duration of eradication regimen
- Where
- South Korea
- Volunteers
- 1,230 people, healthy volunteers welcome
- Sponsor
- Incheon St.Mary's Hospital
HIV-Associated Focal Segmental Glomerulosclerosis, HIV-Associated Collapsing Glomerulopathy
Evaluation of Albuminuria HIV-Infected Patients
This study will examine the following: 1) how common albuminuria and proteinuria are among HIV-positive patients, 2) what causes albuminuria or proteinuria in these patients and 3) whether the condition becomes more severe over…
- Conditions
- HIV-Associated Focal Segmental Glomerulosclerosis, HIV-Associated Collapsing Glomerulopathy, Proteinuria, Albuminuria
- Trial name
- NCT00524992
- Where
- 2 sites in United States
- Volunteers
- 252 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Helicobacter Pylori, Drug Resistance, Multiple
14-day Susceptibility-guided Bismuth Quadruple Therapy for Multiple Drug Resistant H. Pylori Infection
The goal of this clinical trial is to learn if the 14-day susceptibility-guided bismuth quadruple therapy works to treat multiple drug resistant Helicobacter pylori (H. pylori) in adults.
- Trial name
- BSUS-2 (NCT06687499)
- Testing
- Bismuth-based susceptibility-guided treatment
- Where
- Taiwan
- Volunteers
- 46 people
- Sponsor
- National Cheng-Kung University Hospital
HIV (Human Immunodeficiency Virus), Metabolic Syndrome
Effect of Diet-induced Weight Loss on HIV-associated Metabolic Syndrome
Obese HIV-positive women with Metabolic Syndrome (HIV-MS) and obese HIV-negative women with Metabolic Syndrome will be studied before and after achieving moderate (6%-8%) diet-induced weight loss.
- Conditions
- HIV (Human Immunodeficiency Virus), Metabolic Syndrome, HIV Infections
- Trial name
- NCT00857298
- Testing
- Dietary Intervention
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Drug Resistance, Bacterial
Epidemiology of Antimicrobial-use and Antimicrobial-resistant Infections in Four Hospitals in Thailand
The main goal of this retrospective observational study is to understand how stepping down antibiotic treatment (called antibiotic de-escalation) affects patients who receive it compared to those who don't after received a…
- Conditions
- Drug Resistance, Bacterial, Bacteremia
- Trial name
- NCT07082465
- Where
- 4 sites in Thailand
- Volunteers
- 108,000 people
- Sponsor
- University of Oxford
Dermatophyte Infection
Role of Oral Voriconazole in the Treatment of Resistant Dermatophyte Infections
Treatment of dermatophyte infection in our country (Pakistan) is becoming difficult due to the developing resistance to traditional antifungal agents.
- Trial name
- NCT06680544
- Testing
- Voriconazole high dose, Voriconazole low dose
- Where
- Pakistan
- Volunteers
- 120 people
- Sponsor
- Sheikh Zayed Medical College
MDR-TB, Immunotherapy
A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB
A Exploratory Study of drug combination (zoledronic acid/interleukin 2) that specifically amplifies Vγ2Vδ2 T cells in combination with anti-tuberculosis chemotherapy for the treatment of MDR-TB.
- Trial name
- NCT05493267
- Testing
- Vγ2Vδ2 T lymphocyte-based immunotherapy, Treatment regimens for MDR-TB
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.